Clinical trials: Breast Cancer, Metastatic Breast Cancer
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00015886
- Testing
- docetaxel, fluorouracil
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Neoplasm Metastasis
Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into the artery for the treatment of brain metastasis(es) from HER2/neu positive breast cancer.
- Trial name
- NCT02571530
- Testing
- Intra-arterial Cerebral Infusion of Trastuzumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwell Health
Metastatic Breast Cancer
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.
- Trial name
- NCT00467012
- Testing
- bevacizumab, Paclitaxel
- Where
- 5 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Chugai Pharmaceutical
HR+/HER2- Breast Cancer, Metastatic Disease
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.
The ATLANT study is prospective, multicentre, non-interventional, observational study. Patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy.
- Conditions
- HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease
- Trial name
- ATLANT (NCT05789771)
- Testing
- Abemaciclib
- Where
- Russia
- Volunteers
- 136 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Cancer, Brain Metastases, Adult
Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis
This trial aims to assess the impact of SRS on overall survival, PFS, radiation toxicity and quality of life as compared to WBRT in oligometastatic brain disease in breast cancer patients.
- Conditions
- Breast Cancer, Brain Metastases, Adult, Stereotactic Radiosurgery, Whole Brain Radiotherapy
- Trial name
- SRSvsWBRT (NCT05144867)
- Testing
- Stereotactic Radiosurgery
- Where
- India
- Volunteers
- 98 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Metastatic Breast Cancer
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Primary objective is to determine the effectiveness of the combination of bortezomib and doxorubicin in patients with metastatic breast cancer.
- Trial name
- NCT00574236
- Testing
- PS-341, doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Breast Neoplasms, Bone Metastases
Circulating Osteocalcin-positive Cells in Breast Cancer Bone Metastasis
Bone metastasis (i.e. cancer cell spreading to bone) is the major clinical problem of advanced breast cancer patients. Bone metastasis is not curable nor preventable.
- Trial name
- COP-BREAST (NCT03814811)
- Testing
- Circulating Osteocalcin-positive (cOC) cells
- Where
- 2 sites in South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- GVHD (NCT00408681)
- Testing
- lithium carbonate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Breast Cancer
Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer
The purpose of this study is to evaluate whether the combination of fulvestrant and ZACTIMA, versus fulvestrant plus placebo, results in a significant decrease in the bone marker, urinary N-Telopeptide (NTx) in postmenopausal…
- Trial name
- ZAMBONEY (NCT00811369)
- Testing
- Fulvestrant + ZACTIMA
- Where
- 13 sites in Canada
- Volunteers
- 126 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer
Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib
To evaluate the efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
- Trial name
- NCT06135194
- Testing
- T-DXd
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing 302 Hospital
Metastatic Breast Cancer
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
This is a single-arm, phase Ib/II study to examine the safety, tolerability and preliminary efficacy of one cycle of Ad-RTS-hIL-12 immunotherapy in women with advanced breast cancer and pre-study SD or PR after completion of a…
- Trial name
- NCT02423902
- Testing
- Ad-RTS-hIL-12, Veledimex
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Alaunos Therapeutics
Triple Negative Breast Cancer
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as…
- Trial name
- NCT04301739
- Testing
- HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- Volunteers
- 522 people
- Sponsor
- Shanghai Henlius Biotech
FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
The purpose of this study is to assess the safety and effectiveness of AZD4547 in combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1 polysomy (FISH4/5) or gene amplification (FISH 6)
- Trial name
- GLOW (NCT01202591)
- Testing
- AZD4547, Exemestane, Fulvestrant
- Where
- 21 sites in Belgium, Czechia and 6 more
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Synchronous Metastasized Breast Cancer, Circulating Tumor Cells
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Primary Operation in synchronous metastasized invasive breast cancer to evaluate the use of local therapy
- Trial name
- POSYTIVE (NCT01015625)
- Testing
- Surgery, Surgery on Demand
- Where
- 14 sites in Austria
- Volunteers
- 90 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Triple-Negative Breast Cancer
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
This multicenter, randomized, double-blind study will evaluate the efficacy and safety of Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with nab-paclitaxel for first/second line treatment of…
- Trial name
- TORCHLIGHT (NCT04085276)
- Testing
- JS001, Nab-Paclitaxel
- Where
- 55 sites in China
- Volunteers
- 531 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
GIST Metastatic Cancer, Breast Metastatic Cancer
Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast
RECIST criteria for evaluating tumor response are often inadequate for the evaluation of anti-angiogenic drugs. An evaluation model of tumor perfusion with contrast-enhanced ultrasonography was developed at Gustave Roussy.
- Conditions
- GIST Metastatic Cancer, Breast Metastatic Cancer, Kidney Metastatic Cancer, Colon Metastatic Cancer
- Trial name
- VARIA-DCE-US (NCT02666690)
- Testing
- CEUS (Contrast-enhanced ultrasound)
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in participants with metastatic or…
- Trial name
- TH3RESA (NCT01419197)
- Testing
- Trastuzumab emtansine, Treatment of physician's choice
- Where
- 184 sites in United States, Australia and 20 more
- Volunteers
- 602 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Circulating Tumor Cell
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients…
- Trial name
- CTCNeoBC-E (NCT05360290)
- Testing
- GILUPI CellCollector®
- Where
- China
- Volunteers
- 484 people
- Sponsor
- RenJi Hospital
Breast Cancer
T1-T2 Breast Cancer: Comparison Between Removal and Preservation of Axillary Lymph Nodes (SINODAR ONE)
Italian Multicentric non inferiority two-arm randomized clinical trial to verify that the experimental treatment (omission of axillary lymph node intervention) in the presence of sentinel lymph node metastases does not lead to a…
- Trial name
- SINODAR ONE (NCT05160324)
- Testing
- Removal of axillary lymph nodes., Preservation of axillary lymph nodes
- Volunteers
- 889 people
- Sponsor
- Fondazione Humanitas per la Ricerca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.